Q-omics provides the consensus-scored ZNF649 profile across patient tissues and cancer cell-line models. ZNF649 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF649 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF649 RNA expression shows 20,054 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ZNF649 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF649 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF649 survival associations across molecular data types. ZNF649 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF649 RNA expression–survival associations across cancer types. High ZNF649 expression shows unfavorable associations in CESC and SKCM, but favorable associations in KIRC, SCLC, GBM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF649 RNA expression.
This table summarizes ZNF649 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF649. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF649 shows lower tumor expression in KIRC, KICH, HNSC, LUSC and KIRP and higher tumor expression in CHOL. The KIRC box plot shows higher ZNF649 RNA expression in normal versus tumor tissue (log2 FC = −0.855, t-test p < 0.001).
This table shows molecular features associated with ZNF649 in patient tissues and cancer cell lines. In patient samples, ZNF649 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF649 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
